Alessandro D. Santin MD

Professor of Obstetrics, Gynecology, and Reproductive Sciences; Clinical Research Program Leader, Gynecologic Oncology Program, Yale Cancer Center

Specialties & Subspecialties

Cancer Center, Yale: Gynecologic Oncology Program

Obstetrics, Gynecology & Reproductive Sciences: Gynecologic Oncology | Ovarian Cancer Program, Early Detection

Education & Training

  • M.D., University of Brescia School of Medicine (1989)
  • Resident, University of Brescia School of Medicine , Obstetrics & Gynecology (1990 - 1993)
  • Fellow, University of Arkansas for Medical Sciences , Gynecology Oncology (1995 - 2000)
  • Fellow, University of California - Irvine Medical Center , Gynecology Oncology (1993 - 1995)

Patient Care

Accepts New Patients? Yes | Patient Type: Adult, Child | Accepts referrals from patients


Clinical Interests

Cancer of the ovary, uterus, vagina, cervix and vulva; Intraperitoneal chemotherapy; Tumor immunology and immunotherapy; Tumor angiogenesis; Radiation biology; Experimental therapeutics in Gynecologic Oncology


Cancers Treated

Cervix, Gestational Trophoblastic Neoplasia, Ovary, Uterus, Vagina & Vulva


Board Certifications

  • Obstetrics & Gynecology, FB (1993)

Clinical Trials

ConditionsStudy Title
Corpus UteriRandomized Phase II Evaluation of Carboplatin/Paclitaxel with and without Trastuzumab (Herceptin) in HER2/neu+ Patients with Advanced/Recurrent Uterine Serous Papillary Carcinoma
The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician's Choice of Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum
A Phase 3 Randomized Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer
An open label Phase I dose escalation study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose of the anti-mesothelin antibody drug conjugate BAY 94-9343 in subjects with advanced solid tumors
Other Female GenitalA Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer

More Clinical Trials...

Edit Profile